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Abstract 
Occupational therapists need a means to efficiently and accurately screen a 
client’s medication management capacity, especially for clients post-stroke. Most 
therapists are not aware of, nor do they utilize specific assessments for medication 
management capacity, partly due to lack of thorough assessments. The purpose of this 
study was to compare the scores of the ManageMed Screen (MMS), the Screening for 
Self-Medication Safety Post Stroke (S5), and the Montreal Assessment of Cognition 
(MoCA) on a population of rehabilitation clients post-stroke to evaluate consistency of 
scores and determine their usefulness in clinical practice. All screens were designed for 
use in occupational therapy; the MMS was validated for the general adult population, the 
S5 for clients post-stroke, and the MoCA is a cognitive screen used with adult clients 
with a variety of diagnoses including stroke. The MoCA was used to explore the potential 
relationship between cognition and medication management capacity. Study participants 
included five clients post-stroke and three occupational therapists. Clients were screened 
by the occupational therapists with the MMS, S5, and MoCA, and clinicians also 
participated in a focus group to assess their perceived usefulness of the screens. Results 
demonstrated that the MMS was consistent with the S5 in identifying the clients who 
performed the poorest. The MoCA has no consistent relationship with either the MMS or 
S5. Additionally, through a focus group, clinicians deemed both the MMS and S5 as 
useful, but felt the MMS was a more useful screen for their clinical practice in regards to 
efficient and practical use with clients post-stroke in a rehabilitation setting.  
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Introduction 
 
This capstone paper presents combined findings from quantitative and qualitative 
studies conducted to determine the usefulness of two fairly new medication management 
screens in occupational therapy practice. The first few sections of this paper provide a 
background to the topic, a literature review highlighting key factors of cognition, stroke 
medication and issues pertinent to medication management capacity post-stroke. 
Medication management capacity screens and a statement of the problem for this 
capstone follows. The research study is then presented in the methodology section 
outlining the design, participants, instrumentation and procedure. Results and discussion 
ensue with a conclusion on the usefulness (e.g. accuracy, efficiency and practicality) of 
the medication management capacity screens. This paper ends with the implications for 
occupational therapy practice and suggestions for future research.   
Background 
The capacity for medication management is of eminent concern for health 
professionals as there is an increase in chronic disease and medication dependency 
among older adults (Orwig, Brandt, & Gruber-Baldini, 2006; Robnett, Dionne, Jacques, 
Lachance, & Mailhot, 2007).  Poor medication management is related to an increased 
number of medication errors, hospital admissions and higher mortality rates in the older 
adult and those with chronic health issues, such as stroke (Elliott & Marriott, 2009; Hayes, 
Larimer, Adami, & Kaye, 2009). Medication management capacity is the result of intact 
higher level cognitive skills which enable a person to be independent and safe with this 
task. In our practice, occupational therapists are charged with assessing medication 
management capacity as it can impact independence and safety with daily functioning.  
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  7 
Statement of the Problem 
Best practice in occupational therapy would indicate the use of comprehensive 
and psychometrically strong tools for client assessment when available (AOTA, 2008). In 
current practice, specifically in the rehabilitation setting, one often will find clinicians 
using clinical inference from observation of activities of daily living or ‘home grown’ 
screens or questionnaires to assess medication management capacity. Health 
professionals, such as occupational therapists, are not good at predicting a client’s ability 
with medication management based on observation; functional ability of this task is not 
always detected in routine assessments or observations (Elliott & Marriott, 2009).  Wales, 
Clemson, Lannin & Cameron (2012) found that occupational therapists often do not use 
standardized assessment in practice due to their readiness, skill, time commitments, 
“motivation, self-confidence, lack of support from management, personal values and 
beliefs and lack of knowledge” or awareness of the availability of assessments (p. 2). 
Clinical judgment of performance of functional tasks, such as medication management, 
when completed in an unstructured and non-standardized manner, leads to decreased 
legitimacy and limited contributions to evidence-based outcomes in occupational therapy 
(Doucet & Gutman, 2013; Elliott & Marriott, 2009).  Using standardized and normed 
instruments in clinical practice can assist with efficiency, documentation of changes in 
status, and improves overall effectiveness of occupational therapy practice (Doucet, 
2013). Thus the approach to medication management capacity screening traditionally has 
not been standardized in occupational therapy, most likely due to lack of awareness of 
available screens and/or screens are not available for a specific population, such as clients 
post-stroke.  
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There are about a dozen screens in the open market labeled as medication 
management capacity screens (Appendix A); however upon further review of these 
screens we find many are not appropriate for use with clients post-stroke as they lack 
research on this population and key components within the screen specifically to assess 
cognitive and physical skills of clients post-stroke. The literature also indicates that 
assessing cognition alone does not equate to an accurate screen for medication 
management capacity, and for the stroke population physical performance must also be 
assessed (Donovan et al. 2008). Thus some of the screens only address cognition. 
Furthermore, many of these screens are profession specific (not occupational therapy), 
diagnosis specific (not stroke), or do not measure medication capacity, but rather 
adherence patterns.   
When reviewing the literature on medication management capacity, the reader 
will find a plethora of research articles which discuss medication compliance or 
adherence. What is of concern for this capstone is the capacity to follow a medication 
routine based on a client’s cognitive and physical performance (not their choice to adhere 
to their prescribed medication routine). For a client post-stroke, the ability to manage 
medications can be impacted by changes in communication skills, physical abilities, 
cognition, behavior, sensation and visual-perception (Kaizer, Kim, Van, & Korner-
Bitensky, 2010). Up to 65% of stroke survivors demonstrate changes in cognitive 
function including attention deficits, memory deficits, and spatial neglect, all of which 
can impact functional recovery and safety with medication management (Donovan et al., 
2008; Wolf, 2006). To ensure clients post-stroke have the physical and cognitive skills 
for safe medication management, screens that are valid and reliable for this population to 
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assess these skills are needed. For this capstone, the focus will be specifically on clients 
post-stroke as this population typically will present with cognitive and physical 
performance deficits that can impact their capacity for safe and independent medication 
management.  
Consensus from the literature also indicates that there is currently no gold 
standard assessment (e.g. best performing test) to measure medication management 
capacity in typical adults, let alone for those with specific diagnoses such as stroke 
(Elliott & Marriott, 2009; Donovan et al., 2008). There are about a dozen medication 
management screens that have been used over a few decades in various professions, but 
all have short-comings for use in occupational therapy and/or for clients post-stroke. As 
of early 2007, no published instrument with sufficient evidence of reliability and validity 
has been published to enable its recommendation for routine use in clinical practice 
(Elliott & Marriott, 2009).   
Since 2007, two medication management screens have been developed and were 
found to be appropriate for use in occupational therapy: the ManageMed Screen (MMS) 
and the Screening for Self-Medication Safety Post Stroke (S5) (Robnett et al., 2007; 
Kaizer et al., 2010). The MMS and S5 were developed to meet the need for occupational 
therapists by addressing cognitive and physical performance skills required for 
medication management. The MMS was specifically developed by occupational 
therapists for assessing medication management with the general adult population; it is 
able to differentiate between adults who need assistance and those who are independent 
with this task (Robnett et al., 2007). The MMS is standardized and has undergone 
validation studies as well (Robnett et al., 2007). The S5 was developed for occupational 
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therapists to assess medication management capacity for clients post-stroke (Kaizer et al., 
2010). The S5 has undergone only one pilot testing by its authors for use with adult 
clients post-stroke; thus the S5 has limited data to support its reliability and validity. 
These screens continue to need clinical research to support their use in specific client 
populations, such as stroke. In a rehabilitation setting for clients post-post, clinicians need 
a practical screen(s) that will accurately and efficiently assess each client’s cognitive and 
physical skills required to manage their medications. Clinicians generally are not using 
standardized assessments nor is there a gold standard for medication management 
capacity screening. This study will review two screens to address this need in clinical 
practice.  
Research Aim 
The purpose of this capstone was to determine which screen(s) is the most useful 
for occupational therapists based on quantitative and qualitative data. Assessing if the 
MMS and S5 are consistent in identifying clients who have poor medication management 
capacity skills can provide occupational therapists with more screening tools to use in 
practice, as there is a lack of standardized assessments for clients post-stroke to assess 
medication management capacity (StrokEngine, 2013a). Furthermore, qualitative 
information about these screens can give insight into their usefulness (defined for this 
capstone as accuracy, efficiency, and practicality) in clinical practice.  Therefore, this 
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Research Questions 
1. How consistent are the ManageMed Screen (MMS) and the Screening for Self-
Medication Safety Post-Stroke Scale (S5) scores for assessing capacity in medication 
management?  
2. How consistent are the ManageMed Screen (MMS) and the Screening for Self-
Medication Safety Post Stroke Scale (S5) scores compared to the Montreal Cognitive 
Assessment (MoCA) for assessing cognition as an indicator for capacity in medication 
management? 
3. Which of the medication management screening tools (or aspects of each screen) offer 
the most clinically relevant information to help inform decision making for treatment and 
discharge planning for medication management capacity for occupational therapy 
practitioners? 
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Literature Review 
Introduction 
This review provides a synopsis of literature about medication management 
capacity versus medication adherence, cognitive and physical performance deficits that 
are essential to consider when reviewing currently available medication management 
screens, and performance factors impacted by medications which clients post-stroke may 
be taking. Additionally, a summary of medication management screens used across 
different professions will be presented to highlight the need to assess these particular 
medication management screens for continued use in occupational therapy. The literature 
review will conclude with a rationale for the need for this capstone study in which 
specific medication management screens are compared for use with clients post-stroke 
and their impact on clinical practice in occupational therapy is investigated.  
Medication Adherence versus Medication Management Capacity 
In the literature, the terms medication capacity and medication adherence are 
often used interchangeably, when in fact theses terms are fundamentally different. 
Medication adherence speaks to patterns or reasons individuals are not taking 
medications and not to the capacity to do so (Orwig, Brandt & Gruber-Baldini, 2006). 
Adhering to medications does not equate capacity to manage medications; for example, a 
client may be able to administer their medications daily, but perhaps are not able to 
follow the proper dose or instructions. Non-adherence includes client reasons for not 
taking medications routinely, which may be due to difficult medication schedules, lack of 
education on use of the medicine, lack of counseling, possible side effects, poor lifestyle 
adaptation, social vulnerability, polypharmacy, physical or cognitive impairments, 
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decreased communication skills, and financial considerations (Hayes et al., 2009; Robnett 
et al., 2007; Stilley, Bender, Dunbar-Jacob, Sereika, & Ryan, 2010). 
In comparison, medication management capacity involves the skills and abilities 
to manage a medication routine; therefore, encompassing the cognitive and physical 
abilities needed to track, plan, and physically manipulate medications (Kaizer et al., 
2010; Robnett et al., 2007). Medication management capacity encompasses a complex set 
of tasks involving intrinsic and extrinsic performance factors that can impact client safety 
(Stilley, et al., 2010). Intrinsic factors include the skills of attention, memory, perception, 
executive function, problem solving, reading, and insight; these skills enable 
understanding, planning, tracking, and taking medications as prescribed (AOTA, 2008; 
Neupert, Patterson, Davis, & Allaire, 2011; Robnett et al., 2007).  Extrinsic factors 
related to managing medications include contexts such as the physical environment 
[home setup, tools or device use], client’s age, social support, cultural influences or 
beliefs, factors such as socioeconomic status, and belief or non-belief in medical 
treatment (AOTA, 2008; Neupert et al., 2011). All of these factors can also influence if or 
how a client will be able to follow through with a medication routine.  
For example, the Medication Management Instrument for Deficiencies in the 
Elderly (MedMaIDE) is a screen designed to assess compliance or adherence of 
medications in the elderly – specifically knowledge of medications, how to take 
medications, and how to obtain medication (Orwig et al., 2006). This assessment does not 
assess cognitive and physical skills needed to safely and independently manage 
medications. A test such as the MMS contains tasks which assess short-term memory, 
safety, planning a task, and physical manipulation of items needed to carry out a 
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medication routine (Robnett et al., 2007). There are a limited number of studies that 
purely research medication management capacity, but by understanding the distinction of 
adherence versus capacity, one will understand how some screens labeled to assess 
capacity are actually assessing adherence, and therefore not beneficial for use in 
occupational therapy practice when the intent is to assess capacity. Some studies that 
discuss adherence were included in the literature review as they do reflect the importance 
of addressing cognition in relation to medication management capacity which can be 
impacted by stroke.  
Cognition, Stroke and Medication Management 
 The literature suggests that a person’s cognition impacts his/her ability to safely 
and effectively manage daily living tasks, such as medication management. Assessment 
of cognitive performance of a client post-stroke is needed in occupational therapy to 
determine the client’s baseline and identify possible deficits from his/her stroke for 
intervention planning and discharge recommendations. Poor cognitive skills have been 
found to impact safety and independence with medication management capabilities in 
research studies time and time again.   
Hayes et al. (2009) investigated the cognitive abilities of healthy independently 
living elders to follow a medication regimen in a five week long study. Thirty-eight 
participants were divided into two groups (high cognitive function [HCF] and low 
cognitive function [LCF]) based on outcomes of cognitive testing using the Alzheimer’s 
Disease Assessment Scale (Graham, Cully, Snow, Massman, & Doody, 2004) and the 
Mini Mental State Exam (Folstein, Folstein, & McHugh, 1975). Researchers added a 
daily vitamin C regime to the participants’ current medication routine. The participant’s 
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ability to manage medications was measured using a seven-day electronic pill bottle that 
tracked the time and frequency the pill bottle was opened. Additionally, a self-assessment 
questionnaire was provided for participants to complete at the end of the study. The 
authors found that the participants in the LCF group had poorer adherence (27.8%) to 
their medication routine than their counterparts in the HCF group (75%) (with 80% 
adherence considered good). This finding could be attributed to the participant’s ability to 
understand, plan and track their medication routines given their degree of cognitive 
impairment. While this study was concerned with adherence patterns, its does signify that 
cognitive function is an important aspect to assess in medication management capacity.  
 There is a general consensus in the literature regarding cognitive decline and 
stroke; “cognitive impairment is higher among stroke survivors than among age-matched 
stroke-free adults” (Wang, Capistrant, Ehntholt, & Glymour, 2012, p. 1).  The study by 
Wang et al. analyzed 10 years worth of data from the Health and Retirement Study (HRS) 
(the HRS is a large, national cohort study of adults 50 years and older, initially without 
stroke) to examine the long-term pre-stroke and post-stroke memory changes among 
stroke survivors. Performance-based and informant-based assessments of immediate and 
delayed memory recall and incidence of stroke were of interest for this study (Wang et 
al.). The authors looked at the annual rate of memory change through linear and 
curvilinear trends and concluded that stroke survivors’ cognitive function significantly 
declined with each passing year. Memory decline among those surviving stroke was 42% 
faster than those with no recorded stroke. Evidence of cognitive impairments can be 
related to ischemic injury, silent strokes, and other stroke symptoms (Wang et al., 2012). 
While this study did not examine medication management capacity, it highlights the 
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importance of screening cognition (including memory and other aspects of cognitive 
functioning required for medication management) post-stroke to ensure safety and ability 
in all pertinent activities of daily living. 
In a study of predictors for health risk management among stroke survivors, 
researchers found that cognitive losses can contribute to stroke as well as being an 
outcome of stroke (Ireland, Arthur, Gunn, & Oczkowski, 2011). Cognitive skill loss is 
associated with older age, is a precursor to stroke (e.g. transient ischemic attacks), and/or 
the incidence of previous stroke increases the risk of having subsequent strokes due to 
clients’ potential inability to effectively manage their health.  Study participants post-
stroke who were found to have executive function decline and/or visual perceptual 
changes led to a higher risk for poor outcomes, such as not having the capacity to follow 
their plan of care (e.g. medication routine, follow up appointments, etc) (Ireland et al., 
2011). This study highlights the need to have a medication management capacity screen 
that is designed for clients post-stroke to accurately and efficiently assess cognitive skills.  
In 2008, Donovan et al., sought to conceptualize cognition for clients post-stroke 
to enable more focused research in this area. Current clinical trials for stroke recovery 
often focus solely on physical recovery, thus the influence of changes in cognition post-
stroke has not been well studied (Donovan et al., 2008). Through an extensive literature 
review, the authors of this study proposed 10 domains of functional cognition related to 
stroke as a means to study recovery centered on vascular distribution, neuroanatomic 
damage, and cognitive impairment following a stroke. The domains include: language 
abilities, reading and writing, numeric/calculation, limb praxis, visuospatial function, 
social use of language, emotional function, attention, executive function, memory 
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(Donovan et al., 2008). For medication management capacity, all these cognitive skills 
are used to plan, track and manipulate medications (Kaizer et al., 2010; Robnett et al., 
2007). When reviewing a potential medication management capacity screen, the domains 
defined by Donovan et al., (2008) should be considered key components to assess in 
relation to medication management capacity. Given the complexity of the skills 
demanded by this health management task, a comprehensive screen incorporating 
performance-based assessments of cognitive and physical skills is needed rather than 
purely a cognitive screen.   
Cognitive and Physical Assessment Post-Stroke 
 Cognition. 
Cognitive function post-stroke is often assessed immediately upon admission to a 
hospital or rehabilitation center, as the presence of cognitive impairment can impact the 
potential for successful rehabilitation (Aggrawal & Kean, 2010). Occupational therapists 
have access to an assortment of cognitive assessments including standardized 
assessments such as the Cognistat (Kiernan, Mueller, Langston, & Van Dyke, 1987), 
Mini Mental State Exam (MMSE) (Folstein, Folstein & McHugh, 1975) or the Montreal 
Assessment of Cognition (MoCA) (Nasreddine et al., 2005) as well as non-standardized 
assessments such as ones devised by clinicians or setting specific developed tests or 
questionnaires. These assessments alone are not sufficient enough to assess medication 
management capacity in clients post-stroke, but should be used to help identify areas of 
cognition (e.g. memory, sequencing) that are negatively impacting safety with medication 
management.  
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The Cognistat is often cited as the gold standard of cognitive assessments as it has 
withstood years of validity and reliability research. This tool assesses language, 
constructions, memory, calculations, and reasoning (Kiernan, et al., 1987). The Cognistat 
has well defined validity and reliability across the lifespan and diagnoses; however, its 
administration is often lengthy and it is suggested the screen be scored by 
neuropsychologists, not always readily available for use by the occupational therapy 
practitioner (Friedman, 2012). The MMSE was designed to be a briefer tool to assess 
language, construction, and memory skills for the detection of cognitive impairment and 
differentiation of dementias (Aggrawal & Kean, 2010). Through further years of research 
the MMSE was found to have poor sensitivity for the detection of mild cognitive 
impairment (Aggrawal & Kean, 2010). To that end, the MoCA was developed as a brief 
screening tool to detect mild cognitive impairment and has been studied for use with 
clients post-stroke (Nasreddine et al., 2005). The MoCA examines attention and 
concentration, executive functions, memory, language, visuoconstructional skills, 
conceptual thinking, calculations, and orientation (Nasreddine, 2013). The MoCA is often 
used in clinical practice as it is brief, assesses an array of cognitive skills and provides a 
cutoff score for poor versus intact performance (Nasreddine, 2013). 
In a study comparing the MMSE and MoCA for clinical use in a rehabilitation 
setting, Aggrawal & Kean (2010) found the MMSE did not perform as well for the 
detection of mild cognitive impairment. Even though the MoCA can take slightly longer 
to administer, the general consensus of occupational therapists is that the MoCA is a 
more comprehensive test, has adequate psychometrics, has multiple versions and 
language options, and has normative values that are easy to understand (Aggrawal & 
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Kean). In a study by Pendlebury, Cuthbertson, Welch, Mehta, & Rothwell (2010), 
researchers found that in a population of clients post transient ischemia attack (TIA), the 
MoCA detected more cognitive deficits than the MMSE. For the purpose of this capstone 
pilot study, the MoCA was therefore used to explore the relationship between cognition 
and medication management capacity for clients post-stroke.  
Physical assessment. 
Physical assessment of motor-performance skills is also completed in hospitals or 
rehabilitation facilities for clients post-stroke (AOTA, 2008). For independence in daily 
occupations, clients need adequate motor-performance skills often compromised by 
stroke. A variety of deficits can occur post-stroke; when classifying a stroke by cerebral 
hemisphere lesion alone, a stroke in the right hemisphere can affect sensory and motor 
skills of the left side of the body, vision, memory and behavior (American Stroke 
Association, 2012).  A stroke in the left hemisphere can affect sensory and motor skills of 
the right side of the body, speech and language deficits, and memory (American Stroke 
Association, 2012). Strokes in general can result in commonly observed motor-
performance skill deficits that impact occupational performance including poor trunk and 
postural control, lower extremity weakness and/or spasticity impacting balance, standing, 
and walking, and upper extremity dysfunction (pain, edema, contracture, weakness, poor 
motor control) (Gillen, 2006; Gillen, 2011).  For the upper extremity alone, this can 
impact reaching and manipulation of the affected limb, thus impacting bilateral hand 
coordination for tasks such as opening containers, pouring water, and manipulating 
medications.  
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Clinicians routinely have access to a variety of motor assessments that ranges 
from impairment-based such as the Fugl Meyer Assessment of Physical Performance 
(FMA) (Fugl-Meyer, Jaasko, Leyman, Olsson, & Steglind, 1975), to performance-based 
assessment such as Chedoke Arm and Hand Activity Inventory (CAHAI) (Barreca, 
Stratford, Lambert, Masters, & Streiner, 2005). The FMA is a stroke-specific, 
performance-based impairment screen. It was designed by a physical therapist to assess 
motor functioning, balance, sensation and joint functioning in clients with post-stroke 
hemiplegia (Fugl-Meyer et al., 1975). Over the years it has often been used as a gold 
standard to measure other assessments against and the FMA has good evidence of 
validity and reliability (StrokEngine, 2013b). Occupational therapists often use a shorter 
version that measures the level of impairment of solely the upper extremity through 
motor function, joint pain, joint range of motion and sensory function (StrokEngine, 
2013b).  Scores from the FMA relay the level of disability on a severity scale, and the 
FMA is thus often used to assess recovery of physical impairment. 
The CAHAI is a functional assessment that assesses the recovery of the arm and 
hand affected by stroke (Barreca et al., 2005). The original CAHAI consists of “13 
functional items that are non-gender specific, involve both upper limbs, and incorporates 
a range of movements and grasps that reflect stages of motor recovery following stroke” 
(StrokEngine, 2013c). It includes items such as: open a jar of coffee, dial 911, draw a line 
with a ruler, pour a glass of water, wring out a washcloth, do up five buttons, dry back 
with a towel, put toothpaste on a toothbrush, cut medium consistency putty, clean eye 
glasses, zip up a zipper, place a container on a table, and carry a bag up the stairs 
(Barreca et al., 2005). The CAHAI has a 7, 8, or 9 item version as well; all versions have 
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demonstrated adequate validity and reliability (StrokEngine, 2013c). Outcomes from this 
screen indicate the level of independence a client has with a specific task aiding in 
treatment planning and assessing recovery. The CAHAI is well accepted by clients and 
clinicians due to the use of real-life objects and scenarios thus strengthening the desire to 
have a medication management capacity screen which uses a similar function-based 
approach to assess a real-life skill.  
Stroke and Medications  
After sustaining a stroke, clients potentially have performance deficits in relation 
to cognitive and/or physical skills; the combination of both can hinder safety and capacity 
for medication management. Factors such as other disease processes, types of 
medications being taken, and the demands of recovery and rehabilitation can additionally 
impact the client’s function as well as stroke location (hemisphere or lobe), type of stroke 
(embolic or hemorrhagic), number of days post-stroke, certain medications types, and 
poor stress and sleep patterns can negatively impact cognition potentially impairing 
function (Yassa, 2012).  
Clients post-stroke generally are older, have comorbidities, may be taking a 
higher number of medications and/or require a specific schedule of prescriptions 
(Ostwald, Wasserman & Davis, 2006). Comorbidities can include depression, 
hypertension, diabetes, congestive heart failure, high cholesterol and atrial fibrillation 
(Ostwald et al., 2006). Complications during stroke recovery can include depression, 
urinary tract infection, limb pain, and the possible use of tubes (for catheterization, 
tracheotomies, or feeding) (Ostwald et al., 2006). Medications for clients post-stroke can 
range from anti-coagulant, anti-platelet, anti-hypertensive, anti-diabetic, anti-depressants, 
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anti-seizure, antibiotics, bowel regime medications, and pain reduction medications 
(Furie et al., 2011; Ostwald et al., 2006). Medications such as antidepressants, beta 
blockers (such as Propranolol), and barbiturates/benzodiazepines (such as Valium) and 
analgesics (such as Morphine or Oxycodone) can mimic neurological disorders, and/or 
impact brain functioning and performance (Yassa, 2012). The combination of 
comorbidities and complications is associated with higher medication use, and in one 
study by Ostwald et al., (2006) clients post-stroke were discharged with an average of 11 
medications in five different drug classifications. Along with a potential for an increased 
number of medications, these medications may also have precautions (e.g. take with 
food), special instructions (e.g. storage), and side effects of which clients must be aware 
(Ostwald et al., 2006). Recognizing the number of medications and the types of 
medications a client is taking can be helpful for the occupational therapy practitioner to 
better appreciate the client’s performance and its impact on medication management 
capacity. 
In summary, to safely manage medications, clients must be able to physically 
manipulate their medications, such as the packaging and pills, and use higher level 
cognitive skills to remember and follow their often complex medications and medication 
routines. There are a limited number of performance-based assessments to assess a 
client’s capacity to manage medication routines, especially for people with high risk 
diagnoses such as stroke.  In the following section of this literature review, a summary of 
current medication management screens is presented. The weaknesses of a number of 
these screens as medication management capacity screens will be presented along with 
more in depth information about and comparison of the MMS and S5 will be presented. 
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  23 
Medication Management Screens 
In current healthcare practice, there are a variety of medication management 
screens. As seen in Appendix A, some screens are used in specific settings, solely for 
research purposes, or in specific disciplines. The few screens that are used in 
occupational therapy often focus solely on cognition, such as the Cognistat or Mini 
Mental State Exam. These tests were not designed to assess medication management 
capacity, but rather the intrinsic skills that are necessary for medication management (e.g. 
memory, attention). The sample of screens listed below (also in Appendix A) will be 
further examined as follows.  
The Self-Administration of Medication (SAM) is used by nurses to assess a 
person’s competence to self-administer medications when used in the acute care setting. 
This assessment uses interview and observation of patients (Manias, Beanland, Riley, & 
Hutchinson, 2006). The Medication Management Ability Assessment (MMAA) is a 
performance-based measure of medication management for patients with schizophrenia 
using role-play. The MMAA is a modification of the Medication Management Test 
(MMT) (Patterson et al., 2002); the MMT was initially designed to assess adaptive 
strategies in patients with dementia with regard to medication management (Gurland et 
al., 1994). It has since evolved to include the HIV population to assess ability to organize 
HIV medications into pill boxes. It has been reported that use of the MMT is simple, but 
that scoring is complex and not always clinically applicable (Farris & Phillips, 2008). 
The Drug Regimen Unassisted Grading Scale (DRUGS) screen is reported to be an easy-
to-administer tool that assesses a highly functioning older adult’s ability in self-
medication; the screen assesses the ability to identify, access, dose and time their 
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  24 
personal medication routine (Edelberg, Shallenberger, Hausdorff & Wei, 2000). The 
Medication Management Instrument for Deficiencies in the Elderly (MedMaIDE) is 
primarily used in research to assess medication adherence (e.g. compliance and 
management) (Orwig, Brandt, & Gruber-Baldini, 2006). The MedTake Test assesses 
understanding of dosage, indications, schedule, and safety through an interview of older 
adults (Kaizer et al., 2010). The fairly new Self-Medication Assessment Tool (SMAT) is 
a comprehensive tool used by pharmacists to assess deficits in self-management of 
medications by looking at function, cognition, self-reported adherence, medication recall 
and purposeful non-adherence (Irvine-Meek, Gould, Wheaton & Todd, 2010; Irvine-
Meek & Gould, 2011).   
All the previously mentioned screens have been critiqued through numerous 
research studies. Some of the mentioned assessments are profession specific (nursing or 
pharmacy), population specific (older adults, clients with dementia or schizophrenia), or 
rely on self-reports or interview for results. Furthermore, many studies did not define 
medication management, raising the question: was the intent to study capacity or 
adherence? Most of these screens have been found to be far removed from the actual 
performance of medication management as these screens are mainly observation, 
question/answer or paper-pencil based. Many of these screens have been critiqued to be 
too time consuming or not applicable to a clinical setting as they do not provide 
functionally relevant information. Moreover, these screens often lack important domains 
such as communication and physical skills when assessing the capacity to manage a daily 
medication routine for clients post-stroke as mentioned by Donovan et al., 2008, Kaizer 
et al., 2010 and Robnett et al., 2007.  
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New screening tools continue to be developed to address the increasing need in 
occupational therapy practice for comprehensive medication management screens that 
assess both cognitive and physical skills in a functionally relevant manner. Two such 
screens are the ManageMed Screen© and the Self-Medication Safety Post Stroke Screen.  
ManageMed Screen©. 
Robnett et al., (2007) developed a quick portable standardized functional test, the 
ManageMed Screen (MMS), to assess the capacity of adults 18 years and older to 
manage a moderately difficult medication routine (e.g. discriminates amongst normal and 
low functioning clients) (Robnett & Moyers, 2007). The MMS assesses medication 
management capacity, an activity of daily living for adults.  The MMS was developed by 
occupational therapists for use by occupational therapists to serve as a quick screen to 
provide a “snapshot of the client’s ability to comprehend information related to 
prescription use” by utilizing four metacognitive questions, 32 questions addressing 
reading, medication knowledge base, problem solving, short-term and prospective 
memory, and calculations, and lastly a performance task to assess the client’s physical 
and cognitive ability to set-up a weekly medication organizer (Robnett & Moyers, 2007, 
p. 2).  
When developing the MMS, authors collected data from a sample of convenience 
of 33 nursing home residents who needed assistance with medication management and 34 
community living elders who were independent with medication management. All were 
tested with the MMS and 40 were also tested with the Cognistat. Exclusion criteria 
include moderate to severe dementia; disease processes were not recorded (therefore 
some participants may have been stroke survivors) (Robnett et al., 2007). The final 
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segment of the test, setting up the pill organizer, was additionally tested on 72 
pharmacists and seven pharmacy technicians in order to establish content validity of the 
MMS. The authors found that participants tended to rate their ability to think and 
remember higher than they actually performed, and age was found to be related to 
performance. The test was able to differentiate the participants who were independent 
from those who required assistance with medication management, and a norms table 
based on age was developed (Robnett & Moyers, 2007). Results would suggest that 
subjective reports of a client’s ability to manage medications may not be reliable, 
especially if there is a cognitive limitation. Rather, objective measures of cognitive and 
physical performance are needed for accurate results in regards to medication 
management capacity.  
As part of the development of the MMS, correlation between the MMS and 
Cognistat scores was conducted; it was determined the MMS is similar to the Cognistat, 
but the tests assess different aspects of cognition (Robnett & Moyers, 2007). The MMS 
and Cognistat assess key cognitive domains of orientation, language, reading and writing, 
numeric/calculation, visuospatial function, attention, and executive function 
(reasoning/judgment) as mentioned in Donovan et al., 2008 and Stilley et al., 2010. 
However the Cognistat does not thoroughly address limb praxis or physical performance 
as does the MMS. The Pearson correlation coefficient showed moderate correlation (r = 
0.696, p = .001), and inter-rater reliability was assessed and ranges were in the 
satisfactory to high range (0.859 to 0.965) (Robnett & Moyers, 2007). Rasch analysis was 
conducted to look at the degree of difficulty of items; the items in the ManageMed 
Screen were deemed to be of moderate difficulty and without ceiling effect for detecting 
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medication management capacity. The MMS is therefore a standardized test that has been 
validated for adults over the age of 18; it is able to distinguish between adults who need 
assistance and those who are independent. However, the MMS has yet to be studied 
specially for use with clients with specific diagnoses or performance limitations, such as 
stroke. The author acknowledges the need for further validity and reliability studies in 
various client populations to ensure its effective use, however as the test is designed to 
distinguish among clients who are independent and need assistance. Thus the MMS 
would be an appropriate tool to use with clients post-stroke based on the performance 
factors assessed (Robnett et al., 2007; R.Robnett, personal communication April, 1, 2013).  
The MMS is available for commercial purchase online; the clinician is provided 
with a thorough test manual, “three simulated pill vials (with candy imitation pills), a 
mock prescription, three realistic medication information sheets, a pill organizer, the test 
forms, and a magnifying glass” (Robnett et al., 2007,  p. 11). As this test is standardized, 
a norms table was developed on a second group of 100 independent adults to determine 
age-related norms, and is found in the test manual (Robnett & Moyer, 2007).  
Self-Medication Safety Post Stroke Screen. 
Authors Kaizer et al., (2010) conducted a literature review to determine if any 
medication management tools in existence could be used with clients post-stroke (the 
MMS was not included in this review). Concluding “none were tailored to the multi-
faceted needs of the stroke population,” the author set out to develop the Self-Medication 
Safety Post Stroke Screen (S5) to meet the needs of occupational therapy practitioners by 
having a tool that can assess medication management capacity that is diagnosis specific 
to stroke (Kaizer et al., 2010, p. 239). The development of the S5 was done in three 
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phases: 1) a literature review of nine medication management tools, 2) the development 
and draft of a new screening tool, and 3) pilot testing of the screen.  
Nine tools were reviewed [Self-Administration of Medication (SAM), The 
Medication Management Ability Assessment (MMAA), The Drug Regimen Unassisted 
Grading Scale (DRUGS), Hopkins Medication Schedule, The Medication Management 
Instrument for Deficiencies in the Elderly (MedMaIDE), Self- Medication Risk 
Assessment Instrument, The Medication Management Tasks, Standardized Medication 
task (SM task), and MedTake Test] as cited in Kaizer et al. (2010) and were found to 
have limitations in their design and clinical use. The main limitations were that none of 
the tools were standardized for clients post-stroke and none met the cognitive or physical 
demands to be used for the stroke population as mentioned by Donovan et al., 2008 and 
Kaizer et al., 2010. From this review, the authors identified factors that needed to be 
included in a new screen for use with clients post-stroke; these included: memory, 
orientation, physical ability, communication and planning an action (Kaizer et al., 2010). 
Test items were then developed and a screen was drafted.  
 The authors had eleven stroke experts review the screen that included five 
occupational therapists, one speech language pathologist, one neurophysiologist and one 
pharmacist. These interviews aided authors to devise a final draft of the screen that was 
then pilot tested on six participants who were purposively chosen. From a post-test 
interview of the six participants, changes were made to the screen for clarification of test 
items and expansion of client instructions.  
The S5 includes basic orientation questions, the manipulation of medication 
bottles, calculating medication doses, immediate and delayed memory recall tasks, 
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manipulating a syringe (if appropriate for the client), completing visual recognition and 
visual spatial tasks, problem-solving questions to assess cognition (orientation; 
immediate and delayed memory recall), communication (comprehension; reading), motor 
function, visual-perception, and judgment/executive functions/self-efficacy (Kaizer et al., 
2010; StrokEngine, 2013d). Preliminary testing was completed on a target population on 
a sample of five subjects; test-rest reliability is still under study, however content validity 
has been reported as satisfactory making it a potential valid and reliable screen 
(StrokEngine, 2013d). Moreover, the S5 reflects some of the cognitive domains of 
concern (memory, initiation, communication and planning) mentioned by Donovan et al. 
(2008), Neupert et al. (2011), and Stilley et al. (2010), and the physical capacities 
highlighted by Robnett et al. (2007). The S5 is the first known stroke-specific medication 
management screen. The S5 is available free online for clinical use; however, the current 
version is based on pilot testing only and thus has undergone only a preliminary 
validation study by its authors (Kaizer et al., 2010). Clinicians are given a one page 
instruction handout for kit assembly and a one page checklist for questions and scoring.  
Summary 
 Occupational therapy practitioners need screening tools that will assess and 
address capacity for medication management and that are objective, quantitative, valid, 
reliable, administered with minimal training, easily and immediately scorable, brief, 
small, portable, and non-threatening to the client to make them useful in the clinical 
setting (Elliott & Marriott, 2009). Adults can be at risk for poor medication management 
capacity due to potential comorbidities along with age-associated changes in function. 
However, adult clients post-stroke are at even greater risk of difficulty with medication 
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  30 
management due to changes in cognitive and physical functioning. After reviewing 
various assessment tools there is no gold standard or widely accepted method or tool, 
especially as many tools measure adherence patterns related to cognition rather than 
capacity to manage medications. Additionally, stand-alone cognitive assessments can not 
be used to assess medication management capacity. Traditional assessments as reviewed 
in Donovan et al. (2008) and Kaizer et al. (2010) do not meet the needs for the stroke 
population as they lack attention to key factors and domains related to cognition and 
physical performance. Additionally many of the screens reviewed for this study are   
paper-pencil assessments that are somewhat removed from the actual performance of 
medication management. While the MMS was not specifically designed for use with 
clients post-stroke, it has strong validity and reliability in which to discriminate among 
adults who are independent with medication management and those who need assistance. 
The S5 was designed to assess medication management capacity of clients post-stroke, 
but continues to need further research to assess reliability, validity, and clinical 
usefulness as its development was based on such a small selected group of participants. 
This capstone study is a pilot study to begin the investigation of how the MMS compares 
to the S5 for assessment of medication management capacity of clients post-stroke in 
regards to consistency of scoring. Factors including scores and clinician feedback will be 
use to assess their usefulness for used with clients post-stroke in a rehabilitation setting.  
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Methodology 
Research Design 
 This capstone is a mixed methods pilot study design including quantitative and 
qualitative data collection and analysis. This study was approved by the IRB at Nova 
Southeastern University and the IRB of HealthSouth Corporation (Appendix D, E).  
Part I: quantitative data was gathered by clinicians trained by the primary investigator to 
assess a client’s medication management capacity post-stroke utilizing two medication 
management screens and a cognitive screen. The purpose was to compare consistency of 
scores from the MMS, S5 and MoCA in relation to detecting medication management 
capacity. Part II: qualitative data was obtained from the clinicians who participated in a 
focus group interview after data collection was completed. The purpose of the focus 
group was to gather information from the clinicians regarding their perceived usefulness 
of the screens by discussing positive and negative aspects of each screens and their use in 
clinical practice with clients who have sustained a stroke. 
Participants 
 
Clinician participants were recruited from New England Rehabilitation Hospital, 
an inpatient rehabilitation hospital, in Portland, Maine (Appendix I, K). Clinicians were 
used in Part I and II of this study.  Clinicians included one male and two females with 
clinical experience ranging from 3 to 15 years. 
Client participants were recruited by clinicians during their rehabilitation stay at 
New England Rehabilitation Hospital, an inpatient rehabilitation hospital, in Portland, 
Maine. Clients were recruited based on specific inclusion/exclusion criteria (Appendix I, 
J). Five clients participated in the study, including three females and two males with a 
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mean age of 72.6 years. Twenty percent of client participants had a right hemispheric 
stroke of embolic origin, days post-stroke ranged from 9 to 17 with a mean of 11.6 days, 
and clients were taking medications ranging from 4 to 13 medications with an average of 
9.8 medications at the time of screen administration.  For visual deficits, 40% were 
reported to have a deficit (field cut or neglect) (client specific demographics also seen in 
Table 1 below).  
Table 1. Client Participant Demographics 
______________________________________________________________________ 









1 80 Male Embolic, Left 
hemisphere 
 
9 10 Neglect & 
field cut 
2 67 Male Embolic, Left 
hemisphere 
 
8 12 Other 
3 86 Female Unknown, Right 
hemisphere 
 
17 13 None 
4 64 Female Embolic, Left 
hemisphere 
 
15 10 None 
5 
 
66 Female Embolic, Left 
hemisphere 
9 4 None 
 
Additional data were collected on each subject including hand dominance, types 
of medication taken in specific categories, self rated score for level of stress and 
difficulty with sleep on a scale of one to five (one being no problem with stress or sleep 
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Part I: Instruments used in data collection include the ManageMed Screen (MMS), 
the Screening for Self-Medication Safety Post Stroke (S5), and the Montreal Assessment 
of Cognition (MoCA) (Robnett et al. 2007; Kaizer et al., 2010; Nasserdine et al. 2005) 
(Appendix F).  
The MMS has 30 questions and performance tasks to assess “reading, medication 
knowledge base, problem solving, short-term and prospective memory, and calculations” 
(Robnett & Moyers, 2007, p. 2).  The MMS is standardized and has strong validity and 
reliability. A sample question for reading, medication knowledge base, problem solving 
is “If this [prescription A] were a prescription from you doctor, would it be safe to take?” 
The client is given a prescription bottle with printed label information to review; the 
client is to note the date the medication expired. Other questions related to problem-
solving, short-term memory, calculation and physical skills include “Can you open these 
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  34 
containers? Count the number of pills. How long will these pills last if taken as 
prescribed?” Lastly, one task in particular requires the client to successfully utilize all 
cognitive skills and assesses physical skills when the patient is asked to set up a pill 
organizer using three medications based on instructions on each prescription bottle while 
recalling that their meals are taken at 8am, noon and 5:30pm. Slots in a plastic organizer 
must be opened and the client puts in the correct number of pills at the correct times. 
Performance on this screen is scored on a 0 or 1 scale with 0 indicating unable to perform 
or performed incorrectly and 1 as performed correctly. The maximum score one can 
obtain is 39 points; the client’s score can then be compared to age-related norms 
developed by the authors.  
Potential impairments that can be distinguished with use of this screen include 
decreased vision, decreased prospective memory, decreased recognition, decreased safety 
awareness, decreased attention to detail, decreased physical ability, decreased calculation 
skills, decreased retrospective memory, decreased organizational skills, and decreased 
insight (Robnett & Moyer, 2007). The findings of these impairments would indicate poor 
medication management capacity and also provide areas for occupational therapist to 
focus either rehabilitation or remediation intervention strategies.  
The S5 has 16 questions on a checklist to assess basic orientation, the 
manipulation of medication bottles, calculating medication doses, immediate and delayed 
memory recall tasks, manipulating a syringe (if appropriate for the client), completing 
visual recognition and visual spatial tasks, and problem-solving questions to assess 
cognition (orientation; immediate and delayed memory recall), communication 
(comprehension; reading), motor function, visual-perception, and judgment/executive 
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functions/self-efficacy (Kaizer et al., 2010; StrokEngine, 2013d). A sample question 
which addresses calculation, visual recognition, and problem solving includes ‘If you 
have to take 2 pills in the morning and 2 at night, show me how you would group the 
pills’ after providing an open bottle with 8 identical white disc-shaped pills. To assess 
physical skills, some test items include providing a syringe without a needle and asking 
the client to demonstrate how to inject their medications or providing the client with a 
bottle of liquid medication and asking them to “Open the bottle and pour out 10ml of the 
liquid into this cup.”  Scoring is completed by indicating if the task was done correctly by 
checking Yes or No boxes beside each question. The score is out of 16 questions; in 
general a higher score of more Yes responses would indicate less difficulty with 
medication management. More importantly, the screen offers specific areas of concern 
when a question is marked as No that can be addressed in occupational therapy 
intervention. Scoring criteria was not developed beyond a yes/no checklist. For the 
purpose of this study, questions marked yes were counted as 1 point. If a client scored a 
14, 15 or 16 on the S5 this equated ‘normal’ performance capacity; if a client scored 10 to 
13 this equated ‘questionable’ performance capacity, and if a client scored 9 or less, this 
equated ‘poor’ performance capacity with medication management. 
For the purpose of this pilot study, the MoCA was also used to assess the clients’ 
cognition and explore the relationship with medication management capacity. The MoCA 
is a performance-based screen to assess cognitive skills which contains 16 test items that 
examine attention and concentration, executive functions, memory, language, 
visuoconstructional skills, conceptual thinking, calculations, and orientation (Nasreddine, 
2013). A sample question to assess attention, concentration, executive function, 
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visuoconstructional skills, and conceptual thinking is drawing a clock; the client is asked 
to draw a clock, place all numbers in the clock and set the time to five past four 
(Nasreddine, 2013). The client is scored based on contour of the clock, correct sequence 
and placement of numbers in the clock along with correct placement of the hands of the 
clock. Points are given based on correct answers/performance of task. Another sample 
item that assesses attention and calculation is asking the client to subtract serial 7s 
starting with number 90; points are given based on correct subtractions. The entire 
assessment is based out of 30 points with 26 points or greater indicting normal cognitive 
performance, thus any score under 26 should be investigated further (1 point is given to 
the final score if the client has less than 12 years of formal education) (Nasreddine, 2013). 
The MoCA has undergone years of research and studies have consistently demonstrated 
excellent validity and reliability (StrokEngine, 2013e).    
 This research project required two kits for the MMS, two kits for the S5 and two 
sets of printed instructions for the MoCA that were provided by the primary investigator. 
Two kits of each were made to avoid delay in data collection should some testing occur 
simultaneously by one or more clinicians. A copy of the testing materials can be found in 
Appendix F. Beyond test scores, secondary information was collected to further explore 
client performance and relationships between screen scores or other factors. Information 
such as client age, gender, hand dominance, stroke hemisphere location, stroke type, 
number of days post-stroke, number of different medications and if specific medication 
types were used, presence of visual impairment, self-rating on perceived level of stress 
and difficulty with sleep, and total number of minutes needed for testing were collected. 
Specific medication types, presence of visual impairment, self-rating on perceived level 
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of stress and difficulty with sleep is interesting secondary data as studies show that 
specific medication, poor sleep and stress impact cognitive performance, and visual 
impairment can also impact the ability to performance certain tasks on these screens 
(Yassa, 2012).  As a means to collect and record data from 3 assessment tools, a data 
collection sheet was devised for clinicians to record information into one location 
(Appendix G). 
 Part II. The instrument that was used in the guided focus group for clinician 
participants was an open-ended interview guide of 10 questions devised by the primary 
investigator. The questions were intended to evoke dialogue among the clinicians to 
solicit feedback regarding their impression of the screens, the value of information 
obtained from testing, advantages or disadvantages of each screen, scoring discrepancies, 
and overall usefulness the screens. A sample question includes “share your impression or 
feedback on the administration of each test, such as ease of setup, clarity of instructions, 
items in test kits, questions asked etc.” The question guide can be found in Appendix H. 
Procedure 
Recruitment. 
 With approval from the IRB at HealthSouth and IRB at Nova Southeastern 
University (Appendix D, E), clinician participants were recruited to participate in this 
capstone pilot study during a 4 week period. A presentation was provided to the inpatient 
occupational therapy department to recruit interested clinicians. Emails were exchanged 
as needed to clarify inclusion criteria and set-up a time to consent their participation. 
Inclusion criteria included: one year experience on the “Stroke Team” at the inpatient 
rehabilitation center as an occupational therapist, show interest in using medication 
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management capacity screens to better serve their clients, be willing to participate in 
training sessions, test clients for data collection [part I], and participate in a focus group 
[part II]. As clinicians were part of data collection procedures for this research study, they 
were included as research assistants for this study in the IRB protocol and were required 
to complete the CITI training and adhere to the approved IRB protocol.  
 Client participants were patients recruited from New England Rehabilitation 
Hospital (an inpatient rehabilitation center in Portland, Maine) during a 6 week period. 
Five of seven clients recruited consented to participate in the study. Participants were 
recruited based on the following inclusion/exclusion criteria: cognitively intact to consent, 
adult with the diagnosis of stroke, taking daily prescription medication(s), without 
moderate to severe receptive or expressive aphasia (4 or greater on functional 
independence measure (FIM) for comprehension and expression), able to read or write in 
English, and the participant was 72 hours from discharge from acute rehabilitation. 
Clients were flagged by the rehabilitation director and occupational therapy clinical 
leader at New England Rehabilitation Hospital when the client was anticipated to be 
discharged, and were presented with the study. They then determined their interest in 
participating. Clients were provided with written information and consent forms to 
participate (see Appendix I, J). A mutually convenient time for testing was scheduled 
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Training. 
Clinicians were recruited from the New England Rehabilitation Hospital and 
participated in four hours of training prior to client recruitment and data collection. Prior 
to direct training, clinicians were provided with a packet of information detailing the 
research study’s introduction, purpose of research, overview of tests and target 
population and overview of the commitment for participation (e.g. training, data 
collection, focus group participation). Four clinicians consented to participation in the 
study, and three were able to complete all trainings and collect data. Clinicians were also 
provided with sample test packets of the MMS, S5, and MoCA, and test kits to 
familiarize themselves with these prior to training. The four hours of training (two 
sessions of two hours each) were scheduled based on staff availability and rehabilitation 
director approval for date and time of day. 
The first session was devoted to introduction, practice, and competency testing to 
establish inter-rater reliability for the MoCA.  An informal presentation by the primary 
investigator was given, along with supervised practice between clinicians. To establish 
inter-rater reliability, a clinician tested the primary investigator who role played a client. 
The session was observed by the participating clinicians for scoring. The primary 
investigator then assessed inter-rater reliability based on each question and overall score 
for the assessment.  
The next two hour session consisted of the same format but was for the MMS and 
S5. Again an informal presentation by the primary investigator and co-investigator (R. 
Robnett) was given, along with supervised practice between clinicians. To establish inter-
rater reliability, the co-investigator tested the primary investigator who was again role 
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playing a client. The clinicians observed and scored on an individual basis. Score sheets 
were reviewed after these training sessions, but before participant data collection. An 
acceptable level of inter-rater reliability was established at 80% agreement of each test 
(Tickle-Degnen, 2008). For the MoCA, there was 100% inter-rater reliability, for the 
MMS there was 96.875% inter-rater reliability and for the S5 there was 91.964% inter-
rater reliability (Appendix B). For any one item that was below 80% inter-rater reliability, 
the question and scoring method was reviewed with clinicians for clarification. Inter-rater 
reliability did not need to be reestablished for these test items as the criteria was to have 
an overall inter-rater reliability of 80% for the entire test score.  
Clinicians were also trained in the use of the de-identified data collection sheets 
(Appendix G) and procedures for data storage during the study were established. Once 
clinicians completed their screen training and CITI computer training for human research, 
amendments were sent to IRB with their names to be added to the protocol as research 
assistants. Approval was obtained to add clinicians as research assistants enabling the 
start of data collection from clients (Appendix L).  
Data collection part I. 
 Data collection lasted 6 weeks for a minimum of five client participants. Test 
packets (including de-identified data sheets, instructions for the MoCA, and score sheets 
for the MMS and S5) were made available by the primary investigator. Prior to testing, 
clinicians gathered basic information about the participant from the medical chart and 
indicated the information on the Data Collection sheet (Appendix G). Clients were given 
information about the assessment (e.g. purpose, duration) by the trained clinicians to 
confirm consent and to remind the client the assessment could be stopped at any time for 
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any reason. When participants consented, they signed the form and began testing. The 
goal for the screening was for clients to complete them all in one day in a quiet, 
designated area.  
 Testing commenced per testing and manual instructions. Information such as age, 
gender, hand dominance, stroke location/type, days post-stroke, medication questions, 
presence of visual impairment and ratings for stress and sleep were always completed 
first and in numerical order. Questions for the screen score of the MoCA, MMS, and S5 
(questions 13, 14, 15) were not always listed in the same numerical order on each data 
collection sheet to enable random order of testing of the screens between clients. 
Clinicians were told to complete each screen in the order in which they were listed on the 
data sheet and not necessarily numerical order for questions 13, 14, 15.  
Blank test packets were kept in labeled folders with instructions in the 
rehabilitation director’s office; completed test packets were kept in a secured drawer in 
the locked office of the rehabilitation director for the duration of the study. Once data 
collection was completed, the primary investigator collected the data sheets ensuring no 
participant identifier/confidential information was on the data sheets. This data was then 
stored in the co-investigators locked office at the University of New England, Portland, 
Maine. 
Data collection part II.           
After the clinicians completed a minimum of five assessments and six weeks from 
the start of data collection, the clinicians participated in a 1 hour and 30 minute focus 
group interview. The interview took place in the office of the clinical leader at New 
England Rehabilitation Hospital of Portland, Maine at a convenient time for the clinicians. 
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Due to the small sample size of clinicians, the interview was transcribed verbatim by 
hand by the primary investigator during the interview process. The primary investigator 
facilitated the discussion with focus on: clinician feedback on administration of each 
screen (ease, setup, instructions etc.), value of data obtained from the screens, advantage/ 
disadvantage of each screen, and usefulness of the screens to clinical practice. The 
interview guide can be found in Appendix H.  
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As seen in Table 3, compared to the normative scores by age, client 1 scored 
within one standard deviation above the mean score for the MMS, ‘normal’ performance 
on the S5, and below the mean score for the MoCA. Client 2 scored well above one 
standard deviation of the mean score for the MMS, ‘normal’ performance on the S5, and 
above the mean score for the MoCA. Client 3 scored within one standard deviation below 
the mean score on MMS, ‘questionable’ performance on the S5, and at the mean for the 
MoCA. Client 4 scored within one standard deviation below the mean score for the MMS, 
‘normal’ performance on the S5, and below the mean for the MoCA. Client 5 scored 
within one standard deviation above the mean score for the MMS, ‘normal’ performance 
on the S5, and at the norm for the MoCA.  




*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007) 
**S5:14, 15 or 16 = ‘normal’ performance capacity;  
         10 to 13 = ‘questionable’ performance capacity;  
         9 or less = ‘poor’ performance capacity 
***MoCA: 26 or better = normal performance  
Client MMS 






























(29 +/- 3.39) 
14 26 
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Secondary Data 
From the secondary data collected, consistency of mean scores for age, gender, 
hand dominance, right versus left hemisphere stroke, embolic versus hemorrhagic stroke 
and medication type between the MMS, S5 and MoCA were compared.  
Age, gender and hand dominance. 
The mean age for client participants was 72.6 years; as seen in Table 4, the 
youngest client at age 64 scored below the norm on the MoCA, but had normal 
performance for the MMS and S5. The oldest client at age 86 scored normal performance 
for the MMS and MoCA, but had questionable performance on the S5. In Table 7, values 
for nonparametric two-tailed test of Spearman’s rho correlations was conducted on the 
client age and screen scores can be found indicating no consistent relationship. 
















*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007) 
**S5:14, 15 or 16 = ‘normal’ performance capacity;  
         10 to 13 = ‘questionable’ performance capacity;  
         9 or less = ‘poor’ performance capacity 
***MoCA: 26 or better = normal performance  
Client MMS 



































(29 +/- 3.39) 
14 26 66 
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As seen in Graph 1 there was no notable difference in performance of male and 
female in all three screens. The mean for males on the MoCA was 24.5 and females were 
23.6 (26 or better = normal performance); the means for males on the MMS was 32.5 and 
females was 29.6 (see Table 3 for age norms by client); and the means for males on the 
S5 was 15 and females was 14 (14, 15 or 16 = ‘normal’ performance capacity; 10 to 13 = 
‘questionable’ performance capacity; 9 or less  = ‘poor’ performance capacity). By means 
alone, both males and females scored below the norm on the MoCA, within age norms on 
the MMS and ‘normal performance’ on the S5 suggesting no notable difference in 
performance. Similarly, there were no notable differences in scores between individuals 
with right hand dominance and left hand dominance as that two male clients were left 
handed and the three females were right handed. 
Graph 1. Mean Scores of Each Screen by Gender and Hand Dominance 
_______________________________________________________________________ 
______________________________________________________________________ 
Stroke location and type of stroke. 
In Graph 2 below, right versus left hemisphere stroke comparison revealed the 
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performance), 26 on the MMS (normal performance) and a 13 on the S5 (‘questionable’ 
performance).  The remaining clients had a left hemisphere stroke and scored a mean of 
23.5 on the MoCA (below norm), a 32 on the MMS (normal performance) and a 14.75 on 
the S5 (‘normal’ performance). The consistency that is presented here is that the client 
with a right sided hemisphere stroke had ‘questionable’ performance on the S5 when 
compared to the other clients with a left hemisphere stroke, and the clients with a left 
hemisphere stroke performed below the norm on the MoCA. The client with the right 
sided hemisphere stroke was right handed, thus should have had intact motor skills of 
his/her dominant hand to complete the tasks but may have some mild difficulty with 
memory impacting his/her performance on the S5 (American Stroke Association, 2012).  
The clients with a left side hemisphere stroke were split 50/50 with being right hand 
versus left hand dominant, thus the clients who were right handed may have had some 
difficulty with motor tasks and/or mild speech, language or memory deficits impacting 
performance (American Stroke Association, 2012).   
The means of each screen are the same when comparing stroke location to stroke 
type as the one client who had a right hemispheric stroke from unknown origin. The four 
remaining clients who had an embolic stroke where also the clients who had a stroke in 
the left hemisphere (thus the same distribution of right and left handed comparisons 
above). The only consistency seen here is the clients with an embolic stroke (left 
hemisphere) scored lower than the client with the stroke of unknown origin on the MoCA, 
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Days post stroke. 
As seen in graph 3, when graphing client performance on all screens by clients 
based on days post-stroke, the client with most days post-stroke (client 3) performed at 
the norm for the MoCA and MMS, but ‘questionable’ performance on the S5. The client 
with the least days post-stroke (client 2) performed ‘normal’ all three scores. Clients 1 
and 5 with nine days post stroke had normal performance on the MMS and S5, but Client 
1 scored poorly (below the norm) on the MoCA (similar performance to client 4).  There 
does not appear to be a relationship between days post-stroke and performance from each 
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Number of medications. 
While this study was not investigating clients’ abilities to manage their own 
personal medication routine, data on the number of medications clients were taking at the 
time of testing (Graph 4) was obtained for comparison and to demonstrate the high 
number of medications clients post-stroke must take and the implications on health and 
safety that poor medication management capacity can mean for these clients. In Table 7, 
values for nonparametric two-tailed test of Spearman’s rho correlations was completed 
using the average number of medications (9.8) against each client’s screen score 
indicating no consistent relationship between performance and the number of medications 
















Client and Days post 
Stroke 
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From secondary data collection, clinicians were asked to indicate if the clients 
were prescribed antidepressants, beta blocker, barbiturates/benzodiazepines or analgesics 
(as these can impact cognitive performance). Client 1, 2, 3 took both beta blockers and 
analgesics, client 4 took only analgesics, and client 5 took no medications in these 
categories. From Table 5, the clients taking beta blockers and analgesics on average 
scored higher than the one client taking beta blockers alone for the MoCA and MMS, but 
slightly less than the one client not taking any medication in those categories. The clients 
taking beta blockers and analgesics scored lowest on the MMS, and near the same value 
on the S5 as the client not taking medications in these categories. The one client taking 
beta blockers alone scored best on the MMS and S5 but worse on the MoCA. The final 
client not taking any medicines in these categories scored highest on the MoCA but 
average on the MMS and S5. These variations do not support any type of relationship, 
except that clinicians should be aware of clients taking beta blockers as this does seem to 


















MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  50 
Table 5. Mean Scores of Screens by Medication Category 
 Beta blockers and 
Analgesics 
Beta Blockers Only No Medications in 
these Categories 
 
MoCA 25 19 26 
 
MMS 30 32 31 
 




Clinicians were asked to indicate by reviewing the client’s medical record if the 
client who was participating in testing had any of the following: visual neglect, field cut, 
cataracts, glaucoma or other. Of the five clients, client 1 was reported to have a visual 
impairment of left neglect and a left field cut. Clients 3, 4, and 5 reported having no 
visual impairments and client 2 had ‘other’ marked but not identified. Scores and 
clinician feedback did not indicate the impact of these visual deficits on performance. 
Stress and sleep post-stroke. 
In review of client participant secondary data in regards to self-perceived level of 
stress and difficulty with sleep post-stroke, a five point Likert scale was used (1 = no 
problem, 5 = severe problem). Sixty percent of clients reported little to no stress (less 
than a score of three for three of the clients) since their strokes, and 100% reported little 
to no difficulty with sleep since their stroke (less than a score of two for all clients) 
(graph 5). There does not appear to be a consistent relationship between stress, sleep or 
performance on these screens.  
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 Testing time. 
 
The average time to complete the testing was 72 minutes (which included all three 
 
assessments completed in one sitting.  In Table 7, values for nonparametric two-tailed 
test of Spearman’s rho correlations was conducted on the average time of testing (72 










MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  52 
                                                        Results Part I 
 
Using visual comparison of data and statistical data analysis presented in the 
above sections, the question: “How consistent are the ManageMed Screen (MMS) and 
the Screening for Self-Medication Safety Post Stroke Scale (S5) scores for assessing 
capacity in medication management?” can be answered by reviewing data in Table 6. 
Overall, all clients scored within their age norms on the MMS, and all but client 3 scored 
‘normal’ performance capacity on the S5. Using the Statistical Package for Social 
Sciences (SPSS – version 20), each test score were correlated using nonparametric two-
tailed test of Spearman’s rho correlations. The MMS score was compared to the S5 score 
and was found to be statistically non-significant (r=.671, p=.215).  











*MMS age norms based on client age +/- standard deviation (SD) (Robnett & Moyers, 2007) 
**S5:14, 15 or 16 = ‘normal’ performance capacity;  
         10 to 13 = ‘questionable’ performance capacity;  
         9 or less = ‘poor’ performance capacity 
 
When comparing the client’s performance on the MMS to the S5, the trend 
appears to be the clients who scored the highest on the MMS also scored highest on the 
Client MMS Score 























(29 +/- 3.39) 
14 
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S5 (e.g. Clients 2 and 4 in Table 6). However, this pattern is not consistent as clients 1, 
3and 5 also performed within the norm on the MMS and clients 1 and 5 scored 14 or 15 
on the S5 suggesting ‘normal’ performance capacity. Nonetheless, client 3 who scored 
the lowest on the MMS (but still within age norms) also scored the lowest on the S5 
(‘questionable’ performance capacity). This pattern does not suggest a true pattern of 
consistency between the MMS and S5 scores for higher scores, but was able to detect 
lower scores consistently.  
When looking at secondary data in which other factors are considered in regards 
to mean scores of the screens we find the following (see Table 7-*using nonparametric 
two-tailed test of Spearman’s rho correlations):  
1.) there are  no age* differences between screens, 
2.)there are no notable differences in scores between gender and hand dominance, 
3.) a client with right sided hemisphere stroke had ‘questionable’ performance on the S5  
when compared to the other clients with a left hemisphere stroke; clients with a 
left hemisphere stroke performed below the norm on the MoCA when compared 
to the client with a right sided hemisphere stroke (graph 2),  
4.) clients with an embolic stroke scored lower than that of the client with the stroke of  
unknown origin on the MoCA, but higher on both the MMS and S5 (graph 2), 
5.) clients with lesser days post-stroke on average had ‘normal performance’ on all  
screens (graph 3),  
6.) there are  no differences between number of medications* and screen scores (graph 4) 
7.) a client taking beta blockers alone scored the lowest on the MoCA suggesting this  
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  54 
medication category does seem to impact cognition – thus performance on 
cognitive screens (Table 5),  
8.) there is no significance with visual impairments on performance between clients,  
9.) there is no significance regarding ratings of stress and sleep (graph 5), and  
10.) there is no significance among duration of time* and screen.  
Just as the nature of stroke leads to variable presentations and outcomes among 
clients, so does it appear that the only true comparative relationship of the MMS and S5 
based on this sample, is that the MMS was consistent with the S5 in regards to 
identifying the client who consistently scored the lowest on the MMS and S5 (client 3) 
which is where occupational therapy would need to provide intervention. 
Table 7. Spearman’s Rho Correlations of Secondary Data 
________________________________________________________________________ 
  Correlation Coefficient Significance* 
 
Age vs. MMS .-700 p = .188  
 
Age vs. S5 -.447 p = .450 
 
Number of Medications 
vs. MMS 
 
-.205 p = .741 
Number of Medications 
vs. S5 
 
-.229 p = .710 
Number of Medications 
vs. MoCA 
 
.368 p = .542 
Time vs. MMS 
 
.791 p = .111 
Time vs. S5 
 
.412 p =.490 
Time vs. MoCA -.216 p = .727 
 
*significant is p =.001, thus no relationships of significant value in this study  
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 To answer the second research question, “How consistent are the ManageMed 
Screen (MMS) and the Screening for Self-Medication Safety Post Stroke Scale (S5) 
scores compared to the Montreal Cognitive Assessment (MoCA) for assessing cognition 
as an indicator for capacity in medication management?” using visual comparison of data 















When comparing client scores from the MMS and the MoCA, the general trend 
was a client who scored normal performance on the MoCA also scored ‘normal’ 
performance based on age for the MMS (e.g. Client 2, 3, 5 in Table 3). Clients who 
scored below the norm on the MoCA, scored within one standard deviation on the MMS 
Table 3.  Client Scores on MMS, S5, and MoCA 
___________________________________________ 
Client MMS 






























(29 +/- 3.39) 
14 26 
___________________________________________ 
*MMS age norms based on client age +/- standard deviation (SD)  
                                                              (Robnett & Moyers, 2007) 
**S5:14, 15 or 16 = ‘normal’ performance capacity;  
         10 to 13 = ‘questionable’ performance capacity;  
         9 or less = ‘poor’ performance capacity 
***MoCA: 26 or better = normal performance  
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still indicating ‘normal performance’ (e.g. Client 1, 4 in Table 3). There is no consistency 
between the MoCA and MMS.  
When comparing the MoCA to the S5, we find clients 1 and 5 who scored below 
norms on the MoCA scored within ‘normal’ performance on the S5; conversely, client 3 
who scored ‘questionable’ performance on the S5 scored at the norm on the MoCA. 
There does not appear to be a consistent relationship between the S5 and the MoCA.  
Using Statistical Package for Social Sciences (SPSS – version 20), the test scores 
for the MMS and MoCA were correlated using nonparametric two-tailed test of 
Spearman’s rho correlations (Table 7). The MMS score was correlated to the MoCA 
score and was not found to be significant at a value of .205 with p=.741. The S5 score 
was also correlated to the MoCA score using SPSS and was found to have a non-
significant value of -.287 and p=.640.   
From the comparison of the both the MMS and S5 to the MoCA for consistency 
of scoring, we can conclude based on this sample, that there is not a consistent 
relationship with scores for medication management capacity and cognition.  Normal 
performance based on norms of the MMS does not indicate ‘normal’ performance on the 
MoCA, much like ‘normal’ performance on the S5 does not indicate ‘normal’ 
performance on the MoCA. However, the MMS and S5 were similar is scoring in regards 
to indicating the same client who scored the lowest on both perhaps suggesting the 
screens are able to detect those who have ‘normal performance capacity’ versus those 
who have ‘poor performance capacity’ for medication management. However, any 
relationships or trends noted must be interpreted with the utmost caution.  
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Data Part II  
Thematic qualitative analysis from the transcribed focused group data was 
completed for data analysis of part II. The process used the following steps as described 
by Creswell (2009): 
1. Organize and prepare thorough transcription of notes  
2. Initial processing for general sense of themes, phrases, keywords 
3. Coding of themes throughout transcript manually 
4. Discussion of any found patterns or themes that have emerged   
5. Analysis and interpretations of themes 
6. Recommendations related to the findings  
The primary investigator conducted and transcribed verbatim clinicians’ 
responses during the focus group. Questions can be found in Appendix H.  
Thematic analysis of all 10 questions and answers led to the development of 
general themes that enables this data presentation. Theme A (questions 1 and 3) entails 
clinician feedback on usefulness of the screens via administration, ease of setup, clarity 
of instructions, test kit assembly/use and advantages/disadvantages of each screen.  
Theme B (questions 2, 4, 5, 6, 8 and 9) relates the use of the screens in clinical practice 
via the value of the data collected for treatment planning and discharge recommendations, 
and clinicians’ impression with the screen’s ability to differentiate adequate from 
inadequate medication management skills. Theme C (questions 7 and 10) relates to the 
clinicians preference of screen for future use and the subjects’ responses to testing.  
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Theme A: Usefulness of the Screens 
Usefulness was defined to the clinicians as being accurate, efficient and practical 
to their work setting and clinical practice. Clinicians did not experience first hand how to 
obtain or put together their testing kits due to the nature of the study and requirements for 
testing prior to data collection. However, clinicians were made aware that the MMS 
comes assembled but needs to be purchased, while the S5 is free but must be assembled 
by the practitioner. A clinician stated the MMS “comes in a complete kit which is helpful 
[efficient and practical] for a busy work setting,” while the S5 requires clinicians make 
their own kit adding a burden to the clinician and can impact accuracy as the screen is 
“less standardized”.  Both kits have “items/pieces that could easily get lost” especially as 
more clinicians start using the kits in practice which could cause efficiency challenges 
(e.g. locating all testing items or replacing missing items) in the future due to the fast-
paced work setting.   
To collect more information on usefulness, clinicians were asked to state 
advantages and disadvantages of each screen where advantages would relate to being 
useful (accurate, efficient, practical) in clinical practice and the disadvantages would 
make the screen less useful. Advantages to the MMS screen as identified by the clinicians 
included: the screen is “more relevant and practical to every life,” test “items are 
realistic,” “good variety of questions and test items,” “generally has easy to follow 
instructions for clinician and client,” and it is “standardized with norm values.”  
Disadvantages to the MMS included: “it’s time consuming” “difficult to score during 
administration,” and “pill box labeling for scoring is not consistent with instructions.” 
The disadvantages make the MMS less useful in practice to clinicians; however clinician 
MEDICATION MANAGEMENT CAPACITY POST-STROKE                                  59 
consensus from the focus group was that advantages outweighed the disadvantages while 
the MMS lacks efficiency in time to conduct and score the test, it contained practical test 
items, and had easy instructions to follow enabling the clinician to be more accurate with 
testing and scoring. 
Advantages to the S5 screen regarding usefulness (accurate, efficient, practical) 
included: “quick, uses easily available items to put the kits together, and has a variety of 
bottles and pills” and is “easy to score and administer at the same time.” “It’s a good tool 
for clients who may be resistive to testing or easily frustrated.”  Disadvantages to the S5 
included: “too simple and too subjective in scoring,” “no way to accurately score or 
interpret results,”  “does not provide enough information,” and it does not appear to be 
“standardized and has no norms values.” These disadvantages make the S5 less useful in 
practice to clinicians in regards to being accurate and therefore a less practical screen to 
use; however clinicians consensus from the focus group was S5 has its place in practice 
for the right client, such as one who may be resistive to more formal testing like the 
MMS. Clinicians did not rule the S5 out from their clinical practice, but felt the MMS 
may be more generally more useful. 
 Clinicians were asked to share feedback on their impressions of the MoCA. They 
reported: “the purpose, directions and scoring is easily understood,” but the MoCA is a 
screen typically used by speech therapy in this setting, “but now it’s nice to understand 
the screen better and be able to compare scores,” and “it’s standardized.” However, 
clinicians reported the MoCA “does not relate to function,” “can be too long and abstract 
for some clients,” and “not a good screen if the client is aphasic.” Clinicians agreed that 
the MoCA would not be a useful tool for assessing medication management capacity as it 
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would not accurately screen the client’s skills; however, it is a worthwhile tool to have 
access to in the practice setting to be able to offer a cognitive screen and it does enable 
interdisciplinary care.  
Theme B: Applicability to Clinical Practice  
Clinicians were asked to discuss the applicability and value of the data obtained 
from the screens and how it would impact clinical practice in regards to treatment 
planning and discharge recommendations. Clinician responses included: “results were an 
eye opener for me [clinician] and client as it identified areas of need or risk,” “enabled 
better discharge planning,” and the screens were very “applicable to this setting.”  With 
these tools “testing will help the entire rehabilitation team be more proactive with 
discharge planning by identifying specific areas to assess in a standardized approach,” 
and “tools such as these can help our department have a more formal process for client 
teaching and programs around medication management.” One clinician felt that if these 
screens were done earlier in the rehabilitation process “referrals to speech could be made 
to help address cognition should they score poorly on the MoCA.” The theme that 
emerged suggests that these screens are applicable to clinical practice in identifying 
clients who may have difficulty with medication management. This information informs 
accuracy of treatment planning, discharge recommendations and referrals to other 
disciplines. 
Clinicians stated the clients generally performed as anticipated based on their 
functional performance of activities of daily living. However, one client (client 4) who 
was doing very well with self-care and mobility performed poorly on the MoCA and was 
receiving speech therapy for cognitive deficits. While this client had normal performance 
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with the MMS and S5, the fact that she scored poorly on a cognitive screen was of 
concern for the occupational therapist. This suggests that the MoCA is applicable to 
occupational therapy practice as it is a means to do more in depth screening of cognition. 
Additionally, one clinician reported one client “did okay on the verbal questions, but did 
not perform as well on motor tasks” which was good to see both on one screen for 
efficiency. Clinicians also reported that some clients did poorly on the MoCA “but 
performed well on the MMS perhaps indicating the MMS is more functional.”  The 
clients who had difficulty with testing “often made up excuses, stating it was not their 
own routine” possible indicating challenges with abstract problem solving. “Higher level 
clients were tested and they found parts of the screen very challenging, such as the pill 
box in the MMS” and then realized how their stroke affected their thinking skills. The 
screens were a good way to start a dialogue with clients about their medication 
management capacity.  
Clinicians were asked to share their impression of each screen’s ability to detect 
medication management skills. Clinicians stated: “All screens provided good info, some 
better than others;” the MMS “did well for assessing memory, used a variety of tests and 
skills, and generally indicated the client’s ability” with medication management. “You 
could detect if the problem was visual, manipulation or memory” from using the MMS. 
The S5 “would be hard to get enough information if you were doing it alone, as it is too 
basic and vague” even though it uses a nice variety of pill and liquid bottles and a variety 
of pill sizes.  As the MoCA assess only memory and not performance of medication 
management, “it would not be a good stand alone test.”  
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In regards to treatment planning and discharge recommendations, clinicians 
reported: “results will help with discharge recommendations especially related to safety,” 
and “enable patient and family education regarding this task at home.” Clinicians felt that 
while collecting data about one week prior to discharge was helpful, had it been done 
earlier in the rehabilitation process “more nurse and doctor communication could have 
happened” facilitating more in depth teaching from multiple disciplines or modification 
or reduction of medications.  
Theme C: Clinician’s Preference 
 Clinicians were asked to consider each screen, their usefulness and applicability 
to practice, in order to state their preference of a screen they are most likely to adopt into 
their practice. Clinicians stated they feel they could make use of all three screens in future 
practice. However, “generally the MMS will be used most often” as clinicians stated in 
theme A the MMS is relevant, practical, realistic, contains a variety of questions and test 
items, easy to follow instructions, and it is standardized with norm values. As the 
occupational therapy clinicians did not typically use the MoCA at this setting, now being 
trained in its use and scoring, clinicians stated: “the MoCA will help broaden the tools we 
use and enable better collaboration with SLP [speech], and its use can help increase 
justification for rehab stay, and/or adding SLP services, and better communication at 
team meetings for discharge planning.” Future plans for focus on medication 
management with the stroke population at this hospital will entail “following through on 
consistent testing, recommendations and teaching and patient education,” and these tools 
can help with that.  
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 Clinicians reported that in general, the clients’ responses to testing were positive, 
they understood the purpose and learned about themselves through the process. Clients 
generally reported most difficulty with the MMS in regards to the pill box organization 
task, an instrumental activity of daily living.  
Clinicians also found areas of the screens that could be improved to enhance 
clinical practice. Specifically, “testing was not as complicated as real life” and it “would 
be helpful if a test could be tailored to the client’s actual medications or routines.”  Also, 
the “pill box scoring on the MMS needs clearer directions for scoring” for the clinician.  
Table 8. Selected Quotes from the Focus Group 
________________________________________________________________________ 
Regarding the MMS screen:  
“relevant and practical to every life,” “good variety of questions and test items” 
Regarding the S5 screen:  
“It’s a good tool for clients who may be resistive to testing or easily frustrated” 
Regarding the MoCA: 
“does not relate to function” 
Overall Comments: 
“results will help with discharge recommendations especially related to safety” 
“generally the MMS will be used most often” 
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Results Part II 
 The three clinicians’ consensus revealed that they felt the MMS was the more 
useful screen of all screens uses when comparing advantages and disadvantages in 
regards to accuracy, efficiency, practicality and clinical relevance. This directly answers 
the third research question, “Which of the medication management screening tools (or 
aspects of each screen) offers the most clinically relevant information to help inform 
decision making for treatment and discharge planning for medication management 
capacity for occupational therapy practitioners?” While the MMS was the longest to 
administer, previously mentioned advantages appear to make it the most clinically useful 
tool for clients post-stroke in this setting when compared to the S5 and MoCA. The MMS 
offers more clinically relevant information by screening visual, cognitive and physical 
performance skills by having clients read medication information and pill bottles, 
manipulate pill bottles and pills, and complete memory and problem solving tasks. The 
filling of the pill organizer of the MMS was the most revealing in terms of where clients 
could have difficulty with managing a medication routine. However, it was also this 
component that was the most challenging for clinicians to administer and score.   
 Clinicians also felt that they would adopt the use of the MoCA in their clinical 
practice, but not as a medication management capacity screen. The MoCA provides 
clinically relevant information as it can detect what areas of cognition are challenges for 
the client (visuospatial/executive, naming, memory, attention, language, abstraction, 
and/or orientation). The use of the MoCA can target treatment towards compensation or 
remediation approaches to the deficits. Additionally, the MoCA is well understood by the 
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other team members and can create a dialogue during team rounds to ensure the client is 
receiving the necessary services while in rehabilitation.  
 The S5 was the least likely of the screens to be frequently used by these clinicians 
as it lacks usefulness and clinically relevant information. The S5 was found to be too 
subjective, vague and the overall score does not relate to a norm. Generally, clinicians 
felt that while the S5 was the quickest and simplest screen to administer, it did not yield 
data with enough depth to be useful. Clinicians did appreciate that a variety of pill sizes, 
colors, and pill or liquid bottles that were included in the screen, but the score was not as 
meaningful. The S5 will continue to be a possible tool that clinicians can offer a client 
should the MMS be too challenging or if the client is resistive to the screening process.  
This qualitative thematic analysis based on clinician feedback suggests that 
overall the MMS offers the most clinically useful and relevant information for treatment 
and discharge planning.   
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Discussion 
Best practice would indicate the use of comprehensive and psychometrically 
strong tools for client assessment; clinicians often choose assessments tools based on 
their usefulness and practicality to their practice (AOTA, 2008). From the literature, 
clinicians were made aware of several medication management screens available on the 
market for use in practice. However, clinicians were also informed of key items that 
should be included in a medication management screen, such as language abilities, 
reading and writing, numeric/calculation, limb praxis, visuospatial function, social use of 
language, emotional function, attention, executive function, memory and observation of 
performance of medication management tasks from the literature of Donovan et al. 
(2008) and Robnett et al. (2007). When comparing these key items to current assessments, 
the only medication management capacity screens remaining that fit these criteria were 
the MMS and S5. The MMS and S5 were chosen for further study in this capstone 
because of their content and format that included cognitive and physical assessments. The 
screens have also shown to have adequate psychometrics that are supported in the 
literature which creates sound assessment tools for use in clinical practice. The purpose 
of this capstone was to compare the consistency of scores of MMS and S5 and MoCA to 
determine their usefulness in occupational therapy practice.  
The results from this pilot capstone study have introduced data for the usefulness 
of the ManageMed Screen and the Screening for Self-Medication Safety Post Stroke for 
assessing medication management capacity for clients post-stroke. While statistical 
significance of scores between the MMS and S5 was not obtained, the most significant 
and consistent finding was a low score on the MMS equated to a low score on the S5. 
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This potentially indicates that the MMS and S5 measure similar constructs of medication 
management capacity for clients post-stroke perhaps supporting the validity of the MMS 
for use with the stroke population. When comparing the MMS, S5 and MoCA, the 
researcher learned there is not a consistent relationship with scores for medication 
management capacity screens and cognition. However, cognition is one factor in 
medication management capacity that can be assessed with the MoCA which enables the 
clinician to determine what area of cognition may be impacting performance with 
medication management.  
The second focus of the capstone utilized qualitative analysis of clinician 
responses for the usefulness of the medication management screens in clinical practice. 
General consensus is that occupational therapy practitioners preferred the use of MMS 
due to the depth and breadth of information the screen was able to provide. This 
information then aids to inform clinical practice regarding client safety with medication 
management. Clinicians did state that the cost of the kit to their department was not a 
deterrent to obtaining and using this kit. Overall, clinicians indicated in their responses 
that the MMS offered the most useful information to inform their practice for clients 
post-stroke as it assesses “reading, medication knowledge base, problem solving, short-
term and prospective memory, and calculations, and lastly a performance” (Robnett & 
Moyers, 2010, p. 2) all crucial to safety and independence with medication management.   
In current practice, occupational therapists are often not using standardized 
assessment for assessing medication management capacity in the rehabilitation setting. 
‘Homegrown’ assessments lack reliability and validity, and using assessments designed 
for other professions does not measure occupational therapy outcomes (Doucet & 
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Gutman, 2013).  Occupational therapy practitioners need to adopt new, valid, reliable, 
easily administered and client-friendly tools to strive for professional excellence and 
effectiveness (Doucet, 2013). It appears the MMS is a useful screen that could be adopted 
in occupational therapy with clients after they have sustained a stroke. 
This capstone pilot study does give merit and cause for on-going research of this 
nature. The trends and clinician comments indicate that there is a difference in client 
performance and utility for each screen. A research study with a greater sample size 
conducted over a longer period of time could yield data that has more statistical 
significance. Further research is needed on the general topic of medication management 
capacity in occupational therapy. Additionally, further research is needed on the use of 
medication management screens for clients post-stroke.  
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Study Limitations 
A number of limitations must be considered in the interpretations of this pilot study’s 
findings. First, the sample size for clients was small (N = 5), and even smaller for 
clinicians (N=3). Because of the small sample size of clients, some clinicians only 
conducted the screens on one client therefore the depth of information provided in the 
focus group was limited. Additionally, the focus group was not audio recorded which 
could have resulted in some loss of meaning or key phrases provided by clinicians.  
Furthermore, the data collected on each screen was only a score; therefore content 
of each test item could not be further analyzed. In regards to the S5, this screen did not 
have norm values to relate the score to; thus the value of the score was left to subjective 
interpretation. Results therefore cannot be generalized and strong conclusions regarding 
comparisons between screens cannot be made.  
Finally, authors of the S5 have indicated a newer version of the S5 is under study 
and literature will be made available soon to the public. Researchers should review the 
literature and research for this newer version and utilize it in future studies. Future studies 
should include more client participants to enable clinicians to conduct screening on more 
than one client for more in depth data.   
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Questionnaire, used by nurses to assess a person’s 






Used with clients with schizophrenia, assessment in 
completed through role-play 
Drug Regimen Unassisted 
Grading Scale (DRUGS) 
 
Assesses a highly functioning older adult’s ability for self-
medication by looking at ability to identify, access, dose 
and time their personal medication routine  
Medication Management 
Instrument for Deficiencies 
in the Elderly 
(MedMaIDE) 
 





Developed for assessment of  adaptive strategies in patients 
with dementia  
MedTake Test (MT) Assesses understanding of dosage, indications, schedule, 
and safety through interview of older adults 
 
Self-Medication 
Assessment Tool (SMAT) 
Used by pharmacists to assess deficits in self-management 
of medications by looking at function, cognition, self-
reported adherence, medication recall  
 
________________________________________________________________________ 
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Appendix B: Inter-Rater Reliability 
 








d score       %   
MoCA  23-May 23-May 17-May 17-May    
 
 
q1 1 1 1 1 1 100% 
 
  
q2 0 0 0 0 0 100%   
q3 1 1 1 1 1 100%   
q4 1 1 1 1 1 100%   
q5 0 0 0 0 0 100%   
q6 1 1 1 1 1 100%   
q7 1 1 1 1 1 100%   
q8 1 1 1 1 1 100%   
q9 no no no no no x   
q10 1 1 1 1 1 100%   
q11 1 1 1 1 1 100%   
q12 0 0 0 0 0 100%   
q13 2 2 2 2 2 100%   
q14 1 1 1 1 1 100%   
q15 1 1 1 1 1 100%   
q16 1 1 1 1 1 100%   
q17 1 1 1 1 1 100%   
q18 1 1 1 1 1 100%   
q19 3 3 3 3 3 100%   
q20 6 6 6 6 6 100%   
score 24/30 24/30 24/30 24/30 24/30 100% overall test score 
         








d score %   
S5  4-Jun 4-Jun 4-Jun 4-Jun    
q1 1 1 0 1 0 50%   
q2 1 1 1 1 1 100%   
q3 1 1 1 1 1 100%   
q4 1 1 1 1 1 100%   
q5 1 1 1 1 1 100%   
q6 1 1 1 1 1 100%   
q7 0 0 0 0 0 100%   
q8 1 1 1 1 1 100%   
q9 1 1 1 1 1 100%   
q10 0 0 0 0 0 100%   
q11 0 0 0 0 0 100%   
q12 1 1 1 1 1 100%   
q13 0 0 0 0 0 100%   
q14 1 1 1 1 1 100%   
q15 0 0 0 0 0 100%   
q16 1 1 1 1 1 100%   
score 11/16 11/16 10/16 11/16 10/16 96.875% overall test score 
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d score %   
MMS  4-Jun 4-Jun 4-Jun 4-Jun    
 
q5 1 1 1 1 1 100%   
q6 0 0 1 1 0 50%   
q7 1 1 1 1 1 100%   
q8 0 0 0 0 0 100%   
q9 1 1 1 1 1 100%   
q10 1 1 1 1 1 100%   
q11 1 1 1 1 1 100%   
q12 2 2 2 2 2 100%   
q13 1 1 1 1 1 100%   
q14 1 1 1 1 1 100%   
q15 0 0 0 0 0 100%   
q16 1 1 1 1 1 100%   
q17 1 1 1 1 1 100%   
q18 0 0 0 0 0 100%   
q19 1 1 1 1 1 100%   
q20 0 0 0 0 0 100%   
q21 1 1 1 1 1 100%   
q22 1 1 1 1 1 100%   
q23 0 0 0 0 0 100%   
q24 1 1 1 1 1 100%   
q25 1 1 1 1 1 100%   
q26 2 2 2 2 2 100%   
q27 1 1 1 1 1 100%   
grid pink 2/3, green 3/3, white 2/4 1, 3, 3 2, 2, 3 2, 3, 2 3, 3, 2 50%, 25%, 50%  
q29 1 1 1 1 1 100%   
q30 1 1 1 1 1 100%   
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Appendix D: HealthSouth Study Approval 
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Appendix E: IRB Approval 
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Screening for Safe Self-medication Post Stroke Scale (S-5) 
 
Instructions for Administration 
Note: If patient wears glasses, make sure they are worn throughout the test. 




1- Pill bottle with childproof cap 
2- Pill bottle without childproof cap 
3- Pill bottle with a pharmacy label: must include the information commonly found on a label 
(medication name, dosage, frequency, time of day to take medication and the name of a 
person) 
4- Liquid bottle with “push and turn” cover and a medicine cup 
5- 1 syringe without needle 
6- 8 disc-shaped white pills (e.g.: shape of a vitamin C) 
7- 1 oval-shaped blue or green gel-capsule pill 
8- 1 oval shaped orange pill 
9- 1 small and 1 larger disc-shaped white pill 
10- Three objects: pen, coin & a key 
 
Diagram #1 - indicating placement of pills for questions #11 and #12 
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Screening for Self-Medication Safety Post Stroke Scale (S-5) 
Evaluator’s name: ____________________    Date: _____________________________ 
Dysphagia (Y / N): _____________________  Mini-Mental State Examination Score (if available): 
______ 
*Concerns and Recommendations (Note further testing/referrals/training needed) 
 
Questions 1-3: Patient needs to succeed in 2/3 questions to continue screening            Yes       No   
1. Say: What month is it? (Accept +/- 1 month from the correct month) 
 
2. Say: What time of the day is it? (Should identify morning, afternoon or evening) 
 
3. Say: Where are we right now? (Should identify name of hospital or ward or site) 
 
4. Provide an open bottle with 8 identical white disc-shaped pills and say: If you have  
to take2 pills in the morning and 2 at night, show me how you would group the pills.  
(Repeat once if needed) 
 
5. Provide a pill bottle label and say: Can you read to me what it says on the label? 
 
6. Present a pen, coin, and key and say: Remember these three objects: a pen, a coin  
and a key. Remove the objects and ask patient to name the objects. Please tell me what 
they are. (Patient must correctly name all 3 objects.) Then say: I will ask you to  
remember these objects later. 
 
7. Provide a pill bottle with childproof cap and say: Open this bottle and take out one pill. 
(If accomplished: skip to #9, If not accomplished: proceed to #8) 
 
8. Provide a pill bottle without childproof cap and say: Open this bottle and take one pill. 
Self-Injection (Assess if necessary) 
 
9. Provide a syringe without a needle and ask patient to demonstrate how to inject their 
medication. Note if patient uses 1 or 2 hands. ____________ 
 
10. Say: Can you name the three objects I showed you earlier? (Patient must correctly  
name 2/3.) 
 
Randomly place 3 pills (blue, orange, and white) in triangle with pill bottle as in diagram  
#1. 
11. Say: Point to the disc-shaped pill, then to the oval pill, and finally to the capsule- 
shaped pill. (Patient must correctly identify all 3) 
 
12. Say: Point to the blue pill, then to the orange pill and finally to the white pill. 
(Patient must correctly identify all 3) 
 
Place 2 disc-shaped pills (large and small) with pill bottle in the middle as in diagram #2. 
13. Say: Point to the large and then to the small sized pill. (Patient must correctly identify  
both pills.) 
 
14. Say: Imagine you need to take 3 pills every day for your blood pressure and you 
only have one pill left. Suppose you cannot go to a pharmacy for 4 days, what do 
you do? (Repeat once if needed) 
 
15. Provide a liquid medication bottle with “push and turn” cover and say: Open the bottle 
and pour 10 ml of the liquid into this cup. (Accept +/- 2 ml from 10ml) 
 
16. Say: Do you feel confident in taking your medication on your own? 
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Appendix G: Data Collection Sheet 
 
1.)Participant # _____      Date: _________ 
2.)Age: ______ 3.)Gender:   female     male         4.)Hand dominance:  right    left 
 
5.)Stroke location:  R hemisphere stroke     L hemisphere stroke 
6.)Stroke type:        Embolic             Hemorrhagic             Unknown 
 
7.)Number of days post-stroke: ________ 
 
8.)Number of different medications currently taking: ________ 
• 9.)circle if any of the participants medications fall into the following categories: 
o antidepressant       beta blocker           barbiturates/benzodiazepines  analgesics  
 
10.) circle:  
Does the participant have:   visual neglect     field cut    cataracts    glaucoma   
Other visual impairment ____________________________ 
 
Ask the participant to rate the following: 
11.) Since your stroke, please rate you level of stress on the scale below: 
NO STRESS   RARELY   EVERY ONCE IN A WHILE   SOMETIMES   ALL THE                        
                 TIME 
            1                    2                                   3                                   4                        5  
 
12.) Since your stroke, please rate your sleep behavior on the scale below: 
NO PROBLEM      RARELY            EVERY ONCE        SOMETIMES      ALL THE TIME 
                              A PROBLEM          IN A WHILE   
            1                         2                             3                            4                                5  
 
13.) Screen score of MoCA (version B): ________ 
 
14.) Screen score of MMS: _________ 
 
15.) Screen score of S5: _________ 
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Appendix H: Focus Group Questions 
 
1. Share your impressions or feedback on the administration of each test, such as 
ease of setup, clarity of instructions, items in test kits, questions asked 
2. Describe the value of information obtained from the tests 
3. What do you see as the advantage or disadvantages of each screen 
4. Do you find the screens applicable to your clinical practice 
5. Did anything surprise you about the participant’s performance on the tests 
6. Did you find any discrepancies between test results and the client’s actual 
performance 
7. What were the participant’s general reactions to testing 
8. Did information from the screens help you devised your treatment plans or 
recommendations for discharge 
9. Do you feel the MMS did well with detecting medication management skills in 
clients post-stroke? The S5? Any recommendations for either test? 
10. Do you have a preference as to which screen you’ll continue to use 
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Appendix J: NOVA Approved Consent Forms Client 
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Appendix K: NOVA Approved Consent Form Clinician 
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Appendix L: NOVA IRB Amendment Approval 
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